title: Impact of metronidazole therapy on preterm birth in women with bacterial vaginosis flora (Gardnerella vaginalis): a randomised, placebo controlled trial.
abstract: OBJECTIVE
  To ascertain whether metronidazole treatment of women with a heavy growth of Gardnerella vaginalis during mid-pregnancy would reduce the risk of spontaneous preterm birth.
  
  
  METHODS
  A multicentre, randomised, placebo-controlled trial.
  
  
  METHODS
  Four metropolitan hospitals.
  
  
  METHODS
  Eight hundred and seventy-nine singleton women with a heavy growth of G. vaginalis or Gram stain indicative of bacterial vaginosis at 19 weeks of gestation.
  
  
  METHODS
  Oral metronidazole (400 mg) or placebo twice daily for two days at 24 weeks of gestation, and at 29 weeks if G. vaginalis found in test-of-cure swab four weeks after treatment.
  
  
  METHODS
  Spontaneous preterm birth less than 37 weeks.
  
  
  RESULTS
  Intention-to-treat analysis showed no difference between metronidazole and placebo groups in overall preterm birth (31/429 [7.2%] vs 32/428 [7.5%]) or spontaneous preterm birth (20/429 [4.7%] vs 24/428 [5.6%]). Among the 480 women with bacterial vaginosis treatment had no effect on spontaneous preterm birth (11/242 [4.5%] vs 15/238 [6.3%]). In the subset of 46 women with a previous preterm birth, women in the metronidazole group showed a significant reduction in spontaneous preterm birth (2/22 [9.1%] vs 10/24 [41.7%], OR 0.14, 95% CI 0.01-0.84). A treatment effect was also found in compliant women with a previous preterm birth and bacterial vaginosis (0/14 [0%] vs 6/17 [35.3%], OR 0.0, 95% CI 0.0-0.94).
  
  
  CONCLUSIONS
  Metronidazole treatment of women with a heavy growth of G. vaginalis or bacterial vaginosis did not reduce the preterm birth rate. Among women with a previous preterm birth, treatment reduced the risk of spontaneous preterm birth. Further studies are required to confirm these findings.
authors.affiliation: Department of Microbiology and Infectious Disease, Women's and Children's Hospital, North Adelaide, SA, Australia.
authors.forename: H M
authors.initials: HM
authors.lastname: McDonald
authors.forename: J A
authors.initials: JA
authors.lastname: O'Loughlin
authors.forename: R
authors.initials: R
authors.lastname: Vigneswaran
authors.forename: P T
authors.initials: PT
authors.lastname: Jolley
authors.forename: J A
authors.initials: JA
authors.lastname: Harvey
authors.forename: A
authors.initials: A
authors.lastname: Bof
authors.forename: P J
authors.initials: PJ
authors.lastname: McDonald
mesh_terms: D000328:Adult; D000994:Antitrichomonal Agents / Q000009:adverse effects / Q000627:therapeutic use*; D005260:Female; D006194:Gardnerella vaginalis; D006801:Humans; D008795:Metronidazole / Q000009:adverse effects / Q000627:therapeutic use*; D007752:Obstetric Labor, Premature / Q000382:microbiology / Q000517:prevention & control*; D011247:Pregnancy; D012307:Risk Factors; D016896:Treatment Outcome; D016585:Vaginosis, Bacterial / Q000150:complications / Q000188:drug therapy*
chemical_list: D000994:Antitrichomonal Agents; D008795:Metronidazole